ASH 2023 | Phase I study of copanlisib plus venetoclax in R/R DLBCL
In this video, Geoffrey Shouse, DO, PhD, City of Hope, Duarte, CA, briefly comments on a Phase I study (NCT04572763) of copanlisib plus venetoclax in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Although this combination of agents was well tolerated, the overall response rate (ORR) and complete metabolic response (CMR) rate were 8%, as only one patient responded. Dr Shouse suggests that the treatment regimen may be active in select genomic subgroups of DLBCL, which would have to be identified. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
